Novo Holdings

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Sparrow Quantum Aps. is a Danish company specializing in quantum technology, particularly in the development of advanced light-matter interfaces. The firm focuses on creating deterministic single-photon sources, which are essential for various quantum technologies. Sparrow Quantum boasts the highest efficiency for on-chip single-photon sources globally, characterized by exceptional photon purity, indistinguishability, and outcoupling capabilities. This cutting-edge technology is rooted in over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which the company holds exclusive licenses for key patents. By leveraging self-assembled quantum dots paired with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interactions, providing critical advancements for its clients in the field of photonic quantum technology.

Sylvan Inc. is a biotechnology company that specializes in the production and distribution of mushroom spawns, including agaricus, pleurotus, shiitake, and casing inoculum. Established in 1946 and based in Kittanning, Pennsylvania, Sylvan operates production and sales facilities across multiple countries, including the Netherlands, France, Hungary, Ireland, South Africa, Australia, and various locations in the United States. The company also provides disease control products for mushrooms, nutritional supplements, and nicolon nets. In addition to its production capabilities, Sylvan supports the food, health, agriculture, and materials industries through solid-state fermentation technology. The company emphasizes a collaborative approach to innovation and value creation in fungal biotechnology. As of 2019, Sylvan operates as a subsidiary of Jiangsu Yuguan Modern Agricultural S&T Co., Ltd.

Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.

Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.

AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets.

Based on our deep science and focused on patients in need.

Convergent Therapeutics is a clinical-stage biotechnology company focused on developing innovative radiopharmaceutical therapies specifically for prostate cancer. The company utilizes a proprietary dual-targeted radionuclide therapy technology, initially developed by Dr. Neil Bander from Weill Cornell Medicine, which is licensed from Cornell University. Its lead product, CONV 01-α, is a monoclonal antibody conjugated with the radioactive alpha particle emitter 225Ac. This therapy is designed to bind to the prostate-specific membrane antigen (PSMA) and, upon binding, internalize to deliver a potent radioactive payload directly into prostate cancer cells. CONV 01-α is protected by multiple U.S. and foreign patents, and if approved by the FDA, it would be the first antibody to deliver a radioisotope specifically for prostate cancer treatment, marking a significant advancement in cancer therapy. Convergent Therapeutics aims to explore dual-targeted combination strategies to enhance cancer treatment efficacy, leveraging various targeting agents and therapeutic doses.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

Single Use Support GmbH, founded in 2015 and headquartered in Kufstein, Austria, specializes in manufacturing heavy-duty single-use plastic containers and packaging products for the transportation of liquids, primarily serving the biopharma industry. The company develops innovative bulk filling systems, including BULK.STREAM and RoSS.FILL, designed to enhance fluid logistics processes and prevent losses due to leakages or bio-contamination. By offering tailored packaging solutions, Single Use Support aims to improve the efficiency and safety of liquid logistics in the pharmaceuticals sector.

Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer. The company was founded in 2021 and is headquartered in Aarhus, Denmark.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Reduced is a food production company focused on creating natural flavor enhancers from upcycled produce and surplus organic materials. The firm specializes in developing food products that utilize ingredients such as seaweed, shore crabs, egg-laying chickens, and bull calf bones, thereby addressing food waste while promoting sustainability. By leveraging these resources, Reduced aims to provide consumers with healthy, environmentally friendly food options that enhance culinary experiences.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Clasp Therapeutics is focused on advancing cancer treatment through its innovative immunotherapeutics platform. The company develops precision medicines designed to enhance the immune system's ability to identify and eliminate challenging tumors that possess common driver mutations, irrespective of the tumor type. By enabling the targeting of cancer-specific markers, Clasp Therapeutics aims to allow for precise and selective destruction of tumor cells, thereby improving therapeutic outcomes in the field of immuno-oncology.

Asgard Therapeutics is a private biotech company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Emerging as a spin-off from Lund University, the company utilizes its proprietary TrojanDC technology to initiate immune responses by leveraging the unique properties of professional antigen-presenting cells. This approach aims to create efficient and personalized gene therapy products that activate robust anti-cancer immune defenses. By offering off-the-shelf solutions, Asgard Therapeutics seeks to provide new treatment options for patients suffering from cancers that are resistant to traditional therapies, thereby expanding the possibilities for effective cancer treatment.

LEXEO Therapeutics is a biotechnology company that specializes in the development of gene therapies, particularly those utilizing adeno-associated virus (AAV) technology. The company’s pipeline includes both rare and non-rare monogenic diseases, with a strong emphasis on hereditary and acquired conditions that present significant unmet medical needs. LEXEO's lead programs and preclinical candidates are primarily developed in collaboration with Weill Cornell Medicine’s Department of Genetic Medicine. The company aims to advance its clinical programs toward commercialization while maintaining an ongoing research partnership with Weill Cornell to enhance its preclinical efforts. Through its innovative approach, LEXEO Therapeutics seeks to transform the treatment landscape for diseases that impose a substantial burden on patients and society.

Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Catalent Pharma Solutions, Inc. provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industry worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials. It also offers analytical chemical and cell-based testing and scientific services, respiratory products formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology, and product development. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as immediate release tablets and capsules. The Sterile Technologies segment provides proprietary and traditional dose forms for separate routes of administration. It offers formulation and development for injectable drugs; and fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats. This segment's blow-fill-seal technology provides integrated dose form creation and filling of sterile liquids in a single process for respiratory, ophthalmic, and other routes of administration. The Packaging Services segment offers packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit doses; and printed components, such as creating package inserts or folding cartons. The company is based in Somerset, New Jersey.

Manipal Hospitals, part of the Manipal Education and Medical Group, is a significant player in India's healthcare sector, particularly in South India. Established over five decades ago, it has grown to become the country's third-largest healthcare group, operating a network of 15 hospitals and three primary clinics. The organization offers comprehensive healthcare services that encompass both curative and preventive care, addressing a wide range of medical issues from minor ailments to complex conditions. Catering to both Indian and international patients, Manipal Hospitals focuses on delivering quality and affordable healthcare, contributing to the well-being of diverse communities.

Elo Life Systems is a biotechnology company dedicated to enhancing human health and wellness through innovative food solutions. The company aims to connect food, agriculture, and health by addressing challenges related to agricultural productivity, nutritional needs, food security, and overall wellness. Elo employs advanced techniques such as precision breeding, genomics, data analytics, and machine learning to develop healthier food alternatives. By focusing on replacing sugar and artificial sweeteners, Elo strives to empower consumers to enjoy their favorite foods while leading healthier lives. Through strategic partnerships within the food systems value chain, the company seeks to create sustainable solutions that benefit both individuals and communities.

Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.

OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments. It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancer patients around the world. It is founded by Bing Yuan, Eric Slosberg, and Andy Fu.

Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective, safe, and disease-modifying treatment options. Hoba Therapeutics aims to offer relief and prevention for chronic pain and hearing loss, addressing significant medical needs for patients suffering from these conditions.

EnergyRe is focused on advancing the clean energy landscape by developing essential energy infrastructure aimed at decarbonizing urban environments. The company's portfolio includes utility-scale transmission and storage solutions, along with onshore and offshore wind generation and solar facilities. Through these initiatives, EnergyRe seeks to provide access to abundant and affordable clean power while supporting the transition to modern, interconnected electric grids.

Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.

MapLight Therapeutics offers a platform designed to discover and develop therapeutics for brain disorders. It combines single-cell transcriptomics and optogenetics to identify novel drug targets and develop effective therapies for brain disorders.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Paratek Pharmaceuticals is a biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in developing and commercializing innovative therapies targeting life-threatening diseases and public health threats for civilian and military use. Its lead products include NUZYRA (omadacycline), a broad-spectrum antibiotic available in both oral and intravenous formulations, designed for treating community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another key product is SEYSARA (sarecycline), developed for the treatment of moderate to severe acne vulgaris. Paratek's research is grounded in novel tetracycline chemistry, and the company has received Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration for its antibiotic candidates. Additionally, Paratek has established collaborative agreements with various organizations, including Tufts University and the U.S. Army Medical Research Institute of Infectious Diseases, to advance its drug development efforts.

HPNow specializes in innovative water and air treatment solutions through the on-site generation of hydrogen peroxide. The company's technology allows for the efficient production of hydrogen peroxide using only water, electricity, and air, resulting in a safe and eco-friendly biocide. By utilizing their compact HPGen™ hydrogen-peroxide generators, HPNow aims to replace conventional disinfectants, such as chlorine, which are facing increasing regulation due to their toxicity. This approach not only offers cost savings and logistical advantages for users but also enhances food, water, and air safety while minimizing the environmental impact associated with traditional disinfectants. Through these advancements, HPNow is positioned to contribute significantly to multiple industries seeking safer and more sustainable purification methods.

Bactolife is a company dedicated to addressing the global challenge of antimicrobial resistance through innovative solutions. Its proprietary Binding Protein ingredients are designed to strengthen the gut microbiome and minimize the risk of gastrointestinal infections in both humans and animals. By focusing on neutralizing harmful pathogens and their toxins while preserving beneficial microbes, Bactolife aims to enhance gut health and reduce reliance on traditional antimicrobials. The company's approach emphasizes the modulation of the gut microbiome to improve overall health outcomes, making a significant contribution to the fight against antimicrobial resistance. Through its developments, Bactolife seeks to empower individuals and communities worldwide in maintaining better health.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, making healthcare more accessible. The platform also allows patients to order laboratory tests that can be conducted at home. Additionally, HaloDoc helps users locate the nearest hospitals and clinics, streamlining the process of obtaining medical advice and services in real-time.

Ellab is a manufacturer specializing in thermal validation and monitoring products, providing solutions that measure, record, and validate critical parameters in thermal processing. The company offers a diverse range of high-precision and modular systems, including wireless data loggers and thermocouple-based instruments, designed to support various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. With a global presence, Ellab sells its products in over 65 countries, focusing on reducing the time-to-market and minimizing the risk of product loss for its clients.

Octave provides mental health care that’s both accessible to people and sustainable for providers. It partners with clients to develop personalized care plans to best suit the individual's needs. Grounded in science, Octave enables clients to experience profound change that is just as measurable as it is meaningful.

Ray Therapeutics is a company that creates novel optogenetic gene therapies for patients with blinding diseases. The company develops technology to study and learn about rare retinal diseases, allowing doctors to cure and treat inherited retinal diseases using optogenetics.

Sangon Biotech Co. is a biotechnology company founded in 2003 as a Sino-foreign joint venture, specializing in the research and development of chemical synthesis of DNA. Over the years, Sangon has established itself as a key player in the global biotechnology market, known for its expertise in DNA synthesis, sequencing, and gene synthesis. The company has invested significantly in its infrastructure, including a manufacturing and industrial base in Songjiang Industrial Park. Sangon offers a wide range of products and services, including molecular biology kits, biochemicals, synthetic genes, oligos, peptide synthesis, enzymes, and laboratory consumables. By providing affordable life science research tools and services, Sangon supports researchers in advancing basic research and product development in the life sciences field.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

AMSilk GmbH, founded in 2008 and based in Munich, Germany, specializes in producing spider silk proteins and other biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film for protective coatings, and biosteel spider silk fibers. Additionally, AMSilk provides wound care products such as SanaSilk, designed to protect the skin, and spider silk-based solutions for surgical applications. Their product portfolio also includes spider silk protein beads and coatings for medical technology, as well as nonwovens for use in filters, wound dressings, and specialty textiles. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company employs a patented biotechnological process to create biodegradable polymers from silk proteins, enabling the production of various forms such as powders, hydrogels, and fibers that are environmentally friendly.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Clever Care Health Plan, Inc. is a healthcare insurance provider that specializes in Medicare Advantage plans, integrating the principles of Eastern and Western medicine. Founded in 2018 and headquartered in Westminster, California, with an additional office in Arcadia, the company offers a range of culturally sensitive healthcare solutions. Its plans include access to services such as acupuncture, herbal remedies, tai chi, and cupping, aimed at enhancing both physical and mental well-being. Clever Care connects its members with diverse networks of hospitals and healthcare providers who are attuned to their cultural needs and language preferences. The company distributes its products through brokers and sales agents, ensuring that Medicare beneficiaries receive the support and services they require.

Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.

Aquafortus specializes in developing non-thermal crystallization technology aimed at treating high-salinity brines generated from various industrial processes, including cooling towers, mining, oil and gas operations, inland desalination, and flue gas desulfurization from power generation. This innovative technology effectively recovers clean water and crystallizes salts, significantly lowering energy consumption compared to traditional methods. By improving the efficiency of liquid transportation and wastewater management, Aquafortus offers a solution that enhances the economic viability of zero liquid discharge systems, helping clients reduce their operating expenses while addressing environmental concerns associated with high-salinity waste.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Elo Life Systems is a biotechnology company dedicated to enhancing human health and wellness through innovative food solutions. The company aims to connect food, agriculture, and health by addressing challenges related to agricultural productivity, nutritional needs, food security, and overall wellness. Elo employs advanced techniques such as precision breeding, genomics, data analytics, and machine learning to develop healthier food alternatives. By focusing on replacing sugar and artificial sweeteners, Elo strives to empower consumers to enjoy their favorite foods while leading healthier lives. Through strategic partnerships within the food systems value chain, the company seeks to create sustainable solutions that benefit both individuals and communities.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Lechun Biology is an enterprise engaged in disposable products and leak detection equipment in the biotechnology and pharmaceutical industries. The company develops and produces disposable biopharmaceutical process equipment and consumables. The products are used for the storage, transportation, filling and leak detection of various samples in biosimilars, vaccines and other biopharmaceutical processes. The core product is a disposable storage bag. Recently completed B+ round of financing. This round of financing will be mainly used for the development of a number of innovative new products, the establishment of a US R&D center, the integration of the upstream industrial chain, the securing of the supply chain, and the expansion of the R&D market operation team at home and abroad.

Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster. They are targeting the growing need for throughput with robust solutions for clinical and large-scale proteomics, and they have a very ambitious business plan to bring their first products to market. They are basing their design on years of experience with nano-UHPLC R&D and application support, critically rethinking the necessary system architectures for successful sample separation before mass spectrometric analysis. Evosep aims to improve quality of life and patient care by radically innovating how protein based clinical diagnostics are performed, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 10 times faster and 100 times more robust than todays’alternatives. Proteomics is about the study of proteins in a biological mechanism, both their individual function and their combined interactions. For clinical proteomics the goal is to be able to quickly and efficiently compare a biological sample against a profile panel of selected proteins in order to deliver a diagnose / verdict of healthy or diseased (within given statistical margins). Such a profile is typically called a biomarker and for official approval, it must be demonstrated successfully on a large population. This calls for fast sample processing and because such clinical samples, in the form of blood or biopsies, are much more crude that the relatively clean cell cultures used in basic research, very robust protocols and consumables are also required.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Doctor Anywhere is a Singapore-based telehealth company that offers an integrated healthcare platform designed to provide on-demand health and wellness services. The platform enables users to access consultations with licensed medical professionals who can deliver diagnoses, prescribe medications, and issue e-prescriptions, all from the convenience of their location. By combining various health services into a single digital interface, Doctor Anywhere aims to simplify the healthcare experience, making it more accessible and aligned with contemporary lifestyle needs. The company is committed to enhancing health outcomes through technology, addressing modern healthcare challenges, and adapting to the evolving preferences of patients.

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Roslin Technologies is an ag-tech and food tech company focused on advancing biotechnologies to enhance protein production. The company specializes in animal stem cells, having developed perpetually self-renewing, pluripotent stem cells that have the potential to revolutionize the cultivated meat market. By providing these innovative cell lines and associated media formulations, Roslin Technologies enables companies in the cultivated meat industry to reduce costs and accelerate their market entry. Additionally, the company leverages its expertise in genomic capabilities to explore cell therapies aimed at treating incurable diseases in animals. Through these efforts, Roslin Technologies is committed to transforming the future of protein production.

Kate Farms, Inc. is a company that specializes in producing vegan meal replacement shakes and tube feeding solutions for both adults and children. Founded in 2011 and headquartered in Santa Barbara, California, with an additional office in Waltham, Massachusetts, the company focuses on developing plant-based formulas that are easy to digest and made from organic ingredients. These products are designed to provide nutrition without common allergens or synthetic additives, making them suitable for individuals with various dietary restrictions and medical conditions. Kate Farms' offerings are available through both prescription and over-the-counter channels, and the company serves a wide range of patients, from those with severe chronic diseases to those with less serious health issues. Its products are distributed through a network of retail stores across the United States and online.

Vestaron Corporation specializes in the development, manufacture, and sale of peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T, Spear-Lep, and Leprotec, which target various pests in vegetables, fruits, and field crops. The company aims to enhance crop safety, efficacy, and sustainability by providing biopesticides that address resistance issues while ensuring safety for workers and the environment. Vestaron has received notable accolades for its innovative solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, recognizing its commitment to environmental stewardship and effective crop protection.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2017. The company focuses on developing human genetics-based therapeutics aimed at addressing ineffective red blood cell production in hematologic diseases. Its innovative pipeline includes therapies such as bitopertin for treating erythropoietic porphyrias and Diamond-Blackfan anemia. Disc Medicine targets the hepcidin metabolism axis and aims to modify fundamental biological pathways related to red blood cell formation and function, including heme biosynthesis and iron homeostasis. Through its portfolio of clinical and preclinical product candidates, the company strives to transform the lives of patients suffering from severe hematologic disorders.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.